Worth reading
31Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Agreements reached under this partnership
Business alliance4534Mochida Pharmaceutical Co.,Ltd.
Alliance partnerPBC Biomed Inc.
Details of the alliance
- 1
Mochida Medical USA, Inc., Mochida Pharmaceutical’s U.S. subsidiary, will collaborate with PBC Biomed Inc. to begin full-scale sales of ReFeel®.
- 2
PBC Biomed Inc. will expand its distribution network across the United States through multiple distributors and promote sales of ReFeel®.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionWith the aim of advancing medical innovation through the commercialization of new technologies in the fields of medical devices, biomaterials and pharmaceuticals, the company works with companies, physicians and universities to put innovative medical technologies into practical use.
LocationMemphis, Tennessee, United States
| Item | Details |
|---|---|
| Name of alliance partner | PBC Biomed Inc. |
| Alliance partner's business activities | With the aim of advancing medical innovation through the commercialization of new technologies in the fields of medical devices, biomaterials and pharmaceuticals, the company works with companies, physicians and universities to put innovative medical technologies into practical use. |
| Alliance partner's location | Memphis, Tennessee, United States |
| Type of alliance | Business alliance |
| Details of the alliance | Mochida Medical USA, Inc., Mochida Pharmaceutical’s U.S. subsidiary, will collaborate with PBC Biomed Inc. to begin full-scale sales of ReFeel®., PBC Biomed Inc. will expand its distribution network across the United States through multiple distributors and promote sales of ReFeel®. |
Items this document does not state (18)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateImpact on Business PerformanceChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To contribute to improving patients’ quality of life through its U.S. initiatives and pursue further growth in the biomaterials business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.